Review



selleckchem cat  (Selleck Chemicals)


Bioz Verified Symbol Selleck Chemicals is a verified supplier
Bioz Manufacturer Symbol Selleck Chemicals manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Selleck Chemicals selleckchem cat
    Selleckchem Cat, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 94/100, based on 62 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/epigenetics+compound+library/Epigenetics+Compound+Library/10__1158_slash_2767___9764__crc___25___0634-116-19-19
    Average 94 stars, based on 62 article reviews
    selleckchem cat - by Bioz Stars, 2026-10
    94/100 stars

    Images

    Related Articles

    Concentration Assay:

    Article Title: Epigenetic buffering of proteotoxic stress by EHMT2 enables meningioma growth
    Article Snippet: .. The CH-157MN established human meningioma cell line was plated at a density of approximately 2000 cells/well in 384-well culture dishes for 24 h. The cells were then exposed in triplicate for 48 h to compounds obtained from the Library of Pharmacologically Active Compounds (LO1280, Sigma) at a concentration of 10 μM, a kinase inhibitor library (L1200, SelleckChem) at a concentration of 2 μM, or an epigenetics compound library (L1900, SelleckChem) at a concentration of 2 μM. ..

    Drug discovery:

    Article Title: Epigenetic buffering of proteotoxic stress by EHMT2 enables meningioma growth
    Article Snippet: .. The CH-157MN established human meningioma cell line was plated at a density of approximately 2000 cells/well in 384-well culture dishes for 24 h. The cells were then exposed in triplicate for 48 h to compounds obtained from the Library of Pharmacologically Active Compounds (LO1280, Sigma) at a concentration of 10 μM, a kinase inhibitor library (L1200, SelleckChem) at a concentration of 2 μM, or an epigenetics compound library (L1900, SelleckChem) at a concentration of 2 μM. ..

    Article Title: Histone Deacetylase Inhibitors as a Therapeutic Strategy to Eliminate Neoplastic “Stromal” Cells from Giant Cell Tumors of Bone
    Article Snippet: The H3F3A p.G34W immunohistochemical stain (RM263, RevMAb, Biosciences, San Francisco, CA, USA) was performed with the Dako Omnis immunostainer (Agilent, Santa Clara, CA, USA) according to the standard diagnostic procedure at LUMC. .. A detailed list of all compounds ( n = 128) included in the epigenetics compound library (L1900, Selleckchem, Houston, TX, USA) is presented in the . .. The histone deacetylase (HDAC) inhibitors romidepsin (S3020, Selleckchem), panobinostat (S1030, Selleckchem), dacinostat (S1095, Selleckchem), quisinostat (S1096, Selleckchem), and fimepinostat (S2759, Selleckchem) were dissolved in DMSO.

    Article Title: Discovery of Competent Chromatin Regions in Human Embryonic Stem Cells
    Article Snippet: .. An aliquot of the Epigenetics Compound Library (Selleck L1900) was purchased from the MSK Gene Editing & Screening core. ..

    Article Title: EZH2 as a major histone methyltransferase in PDGF-BB-activated orbital fibroblast in the pathogenesis of Graves’ ophthalmopathy
    Article Snippet: .. For the screening experiments, orbital fibroblasts were pre-incubated with selective HKMT inhibitors from Epigenetics Compound Library (Catalog No. L1900, Selleck Chemicals, Inc., TX) for 24 h and stimulated with 50 ng/ml of PDGF-BB (Biolegend Inc., USA), either with or without the HKMTs inhibitors for another 24 h. For further experiments on orbital fibroblast activation, only EZH2, G9a and DOT1L inhibitors were used as shown in Supplementary Table . ..

    Article Title: Histone Deacetylase Inhibitors as a Therapeutic Strategy to Eliminate Neoplastic “Stromal” Cells from Giant Cell Tumors of Bone
    Article Snippet: .. The following are available online at https://www.mdpi.com/article/10.3390/cancers14194708/s1 , Table S1: Clinical information of patient samples that were used to establish cell lines of neoplastic “stromal” cells, Table S2: STR profiles of corresponding primary tumor tissues and established cell lines, Table S3: Detailed list of all compounds included in the epigenetics compound library (L1900, Selleckchem), Figure S1: Original tumor of L4040 was diagnosed as GCTB with atypia, Figure S2: Established cell lines show RNA expression of H3F3A-WT and H3F3A p.G34W, and Figure S3: Original blots from all performed Western blots. ..

    Article Title: Epigenetic drug screen identified IOX1 as an inhibitor of Th17-mediated inflammation through targeting TET2
    Article Snippet: .. To assess which molecular components of the epigenetic machinery to target in order to inhibit inflammatory cytokine expression in Th subsets, we screened a commercially available “Epigenetics Compound Library” (purchased from Selleck in 2015) for their potential effects in the proliferation and differentiation of Th1, Th17, and Treg cells. ..

    Article Title: Histone Deacetylase Inhibitors as a Therapeutic Strategy to Eliminate Neoplastic "Stromal" Cells from Giant Cell Tumors of Bone.
    Article Snippet: .. Cancers 2022, 14, 4708 14 of 16 Supplementary Materials: The following are available online at https://www.mdpi.com/article/ 10.3390/cancers14194708/s1, Table S1: Clinical information of patient samples that were used to establish cell lines of neoplastic “stromal” cells, Table S2: STR profiles of corresponding primary tumor tissues and established cell lines, Table S3: Detailed list of all compounds included in the epigenetics compound library (L1900, Selleckchem), Figure S1: Original tumor of L4040 was diagnosed as GCTB with atypia, Figure S2: Established cell lines show RNA expression of H3F3A-WT and H3F3A p.G34W, and Figure S3: Original blots from all performed Western blots. ..

    Article Title: Beyond the Influence of IDH Mutations: Exploring Epigenetic Vulnerabilities in Chondrosarcoma
    Article Snippet: .. Detailed list of all compounds included in the epigenetics compound library (L1900, Selleckchem). ..

    Activation Assay:

    Article Title: EZH2 as a major histone methyltransferase in PDGF-BB-activated orbital fibroblast in the pathogenesis of Graves’ ophthalmopathy
    Article Snippet: .. For the screening experiments, orbital fibroblasts were pre-incubated with selective HKMT inhibitors from Epigenetics Compound Library (Catalog No. L1900, Selleck Chemicals, Inc., TX) for 24 h and stimulated with 50 ng/ml of PDGF-BB (Biolegend Inc., USA), either with or without the HKMTs inhibitors for another 24 h. For further experiments on orbital fibroblast activation, only EZH2, G9a and DOT1L inhibitors were used as shown in Supplementary Table . ..

    RNA Expression:

    Article Title: Histone Deacetylase Inhibitors as a Therapeutic Strategy to Eliminate Neoplastic “Stromal” Cells from Giant Cell Tumors of Bone
    Article Snippet: .. The following are available online at https://www.mdpi.com/article/10.3390/cancers14194708/s1 , Table S1: Clinical information of patient samples that were used to establish cell lines of neoplastic “stromal” cells, Table S2: STR profiles of corresponding primary tumor tissues and established cell lines, Table S3: Detailed list of all compounds included in the epigenetics compound library (L1900, Selleckchem), Figure S1: Original tumor of L4040 was diagnosed as GCTB with atypia, Figure S2: Established cell lines show RNA expression of H3F3A-WT and H3F3A p.G34W, and Figure S3: Original blots from all performed Western blots. ..

    Article Title: Histone Deacetylase Inhibitors as a Therapeutic Strategy to Eliminate Neoplastic "Stromal" Cells from Giant Cell Tumors of Bone.
    Article Snippet: .. Cancers 2022, 14, 4708 14 of 16 Supplementary Materials: The following are available online at https://www.mdpi.com/article/ 10.3390/cancers14194708/s1, Table S1: Clinical information of patient samples that were used to establish cell lines of neoplastic “stromal” cells, Table S2: STR profiles of corresponding primary tumor tissues and established cell lines, Table S3: Detailed list of all compounds included in the epigenetics compound library (L1900, Selleckchem), Figure S1: Original tumor of L4040 was diagnosed as GCTB with atypia, Figure S2: Established cell lines show RNA expression of H3F3A-WT and H3F3A p.G34W, and Figure S3: Original blots from all performed Western blots. ..

    Western Blot:

    Article Title: Histone Deacetylase Inhibitors as a Therapeutic Strategy to Eliminate Neoplastic “Stromal” Cells from Giant Cell Tumors of Bone
    Article Snippet: .. The following are available online at https://www.mdpi.com/article/10.3390/cancers14194708/s1 , Table S1: Clinical information of patient samples that were used to establish cell lines of neoplastic “stromal” cells, Table S2: STR profiles of corresponding primary tumor tissues and established cell lines, Table S3: Detailed list of all compounds included in the epigenetics compound library (L1900, Selleckchem), Figure S1: Original tumor of L4040 was diagnosed as GCTB with atypia, Figure S2: Established cell lines show RNA expression of H3F3A-WT and H3F3A p.G34W, and Figure S3: Original blots from all performed Western blots. ..

    Article Title: Histone Deacetylase Inhibitors as a Therapeutic Strategy to Eliminate Neoplastic "Stromal" Cells from Giant Cell Tumors of Bone.
    Article Snippet: .. Cancers 2022, 14, 4708 14 of 16 Supplementary Materials: The following are available online at https://www.mdpi.com/article/ 10.3390/cancers14194708/s1, Table S1: Clinical information of patient samples that were used to establish cell lines of neoplastic “stromal” cells, Table S2: STR profiles of corresponding primary tumor tissues and established cell lines, Table S3: Detailed list of all compounds included in the epigenetics compound library (L1900, Selleckchem), Figure S1: Original tumor of L4040 was diagnosed as GCTB with atypia, Figure S2: Established cell lines show RNA expression of H3F3A-WT and H3F3A p.G34W, and Figure S3: Original blots from all performed Western blots. ..

    Expressing:

    Article Title: Epigenetic drug screen identified IOX1 as an inhibitor of Th17-mediated inflammation through targeting TET2
    Article Snippet: .. To assess which molecular components of the epigenetic machinery to target in order to inhibit inflammatory cytokine expression in Th subsets, we screened a commercially available “Epigenetics Compound Library” (purchased from Selleck in 2015) for their potential effects in the proliferation and differentiation of Th1, Th17, and Treg cells. ..



    Similar Products

    94
    TargetMol targetmol epigenetic inhibitors
    High-throughput drug screen and MEK inhibitor sensitivity in MRTX1719-resistant NSCLC cells. (A) Composition of the compound library used for drug screen, including SGC <t>epigenetic</t> compounds, FDA-approved oncology drugs, and TargetMol epigenetic <t>inhibitors.</t> (B) IC50 values of MRTX1719 and anisomycin in DMSO and MRTXR cells. Anisomycin was included as a nonselective control in the drug screen. (C) Dose-response curves of DMSO and MRTXR cells treated with the MEK inhibitor selumetinib. Data are presented as mean ± SD. (D) Synergy heatmaps of MRTX1719 and selumetinib in DMSO and MRTXR cells. Synergy mean scores were calculated using the Bliss model with the SynergyFinder+ tool.
    Targetmol Epigenetic Inhibitors, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/epigenetics+compound+library/Histone+Modification+Compound+Library/bio_rxiv__64898__2026__04__16__719008-139-10-10
    Average 94 stars, based on 1 article reviews
    targetmol epigenetic inhibitors - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    94
    TargetMol 380 targetmol epigenetic inhibitors
    High-throughput drug screen and MEK inhibitor sensitivity in MRTX1719-resistant NSCLC cells. (A) Composition of the compound library used for drug screen, including SGC <t>epigenetic</t> compounds, FDA-approved oncology drugs, and TargetMol epigenetic <t>inhibitors.</t> (B) IC50 values of MRTX1719 and anisomycin in DMSO and MRTXR cells. Anisomycin was included as a nonselective control in the drug screen. (C) Dose-response curves of DMSO and MRTXR cells treated with the MEK inhibitor selumetinib. Data are presented as mean ± SD. (D) Synergy heatmaps of MRTX1719 and selumetinib in DMSO and MRTXR cells. Synergy mean scores were calculated using the Bliss model with the SynergyFinder+ tool.
    380 Targetmol Epigenetic Inhibitors, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/epigenetics+compound+library/Histone+Modification+Compound+Library/bio_rxiv__64898__2026__04__16__719008-78-19-20
    Average 94 stars, based on 1 article reviews
    380 targetmol epigenetic inhibitors - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    94
    TargetMol sgc epigenetic compounds
    High-throughput drug screen and MEK inhibitor sensitivity in MRTX1719-resistant NSCLC cells. (A) Composition of the compound library used for drug screen, including <t>SGC</t> <t>epigenetic</t> compounds, FDA-approved oncology drugs, and TargetMol epigenetic inhibitors. (B) IC50 values of MRTX1719 and anisomycin in DMSO and MRTXR cells. Anisomycin was included as a nonselective control in the drug screen. (C) Dose-response curves of DMSO and MRTXR cells treated with the MEK inhibitor selumetinib. Data are presented as mean ± SD. (D) Synergy heatmaps of MRTX1719 and selumetinib in DMSO and MRTXR cells. Synergy mean scores were calculated using the Bliss model with the SynergyFinder+ tool.
    Sgc Epigenetic Compounds, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/epigenetics+compound+library/Histone+Modification+Compound+Library/bio_rxiv__64898__2026__04__16__719008-78-16-20
    Average 94 stars, based on 1 article reviews
    sgc epigenetic compounds - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    94
    Selleck Chemicals selleckchem cat
    High-throughput drug screen and MEK inhibitor sensitivity in MRTX1719-resistant NSCLC cells. (A) Composition of the compound library used for drug screen, including <t>SGC</t> <t>epigenetic</t> compounds, FDA-approved oncology drugs, and TargetMol epigenetic inhibitors. (B) IC50 values of MRTX1719 and anisomycin in DMSO and MRTXR cells. Anisomycin was included as a nonselective control in the drug screen. (C) Dose-response curves of DMSO and MRTXR cells treated with the MEK inhibitor selumetinib. Data are presented as mean ± SD. (D) Synergy heatmaps of MRTX1719 and selumetinib in DMSO and MRTXR cells. Synergy mean scores were calculated using the Bliss model with the SynergyFinder+ tool.
    Selleckchem Cat, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/epigenetics+compound+library/Epigenetics+Compound+Library/10__1158_slash_2767___9764__crc___25___0634-116-19-19
    Average 94 stars, based on 1 article reviews
    selleckchem cat - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    94
    Selleck Chemicals epigenetics compounds library screening epigenetics compounds library
    High-throughput drug screen and MEK inhibitor sensitivity in MRTX1719-resistant NSCLC cells. (A) Composition of the compound library used for drug screen, including <t>SGC</t> <t>epigenetic</t> compounds, FDA-approved oncology drugs, and TargetMol epigenetic inhibitors. (B) IC50 values of MRTX1719 and anisomycin in DMSO and MRTXR cells. Anisomycin was included as a nonselective control in the drug screen. (C) Dose-response curves of DMSO and MRTXR cells treated with the MEK inhibitor selumetinib. Data are presented as mean ± SD. (D) Synergy heatmaps of MRTX1719 and selumetinib in DMSO and MRTXR cells. Synergy mean scores were calculated using the Bliss model with the SynergyFinder+ tool.
    Epigenetics Compounds Library Screening Epigenetics Compounds Library, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/epigenetics+compound+library/Epigenetics+Compound+Library/pm41792232-60-0-15
    Average 94 stars, based on 1 article reviews
    epigenetics compounds library screening epigenetics compounds library - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    94
    Selleck Chemicals epigenetics compounds library
    a Stable overexpression of VHL-HA plasmid in 786-O cells (a VHL mutated RCC cell). Western blotting detected the protein level of VHL, HA tag and its downstream target genes HIF-2α in this VHL-isogenic 786-O cell pair. Data are shown as the mean ± s.d., n = 3. b A schematic diagram of synthetic lethal drug screen using VHL-isogenic 786-O cell pair on the <t>Epigenetics</t> Compound Library. c Selectivity index (fold-difference in IC 50 values between VHL −/− and wtVHL OE cells) plot to identify top five synthetic lethal drug candidates. d–g Dose–response curve of 786-O VHL-isogenic cell pair ( d ) and VHL non-isogenic cell pair ( f ) treated with decitabine for 72 h. Data are shown as the mean ± s.d., n = 3. The representative images of cell density with the indicated concentration of decitabine for wtVHL OE and VHL −/− ( e ) and Caki-1 and 769-p ( g ) cells. h , i Azacitidine effect on cell viability in 786-O VHL-isogenic cell pair ( h ) and VHL non-isogenic cell pair ( i ). Data are shown as the mean ± s.d., n = 3. ** P < 0.01, *** P < 0.001 between two indicated groups, Student’s t -test. j , k Dose–response curve of 786-O VHL-isogenic cell pair treated with RC-3117 ( j ) and SGI-1027 ( k ). Data are shown as the mean ± s.d., n = 3. l Chemical structures of DNMT inhibitors used in this study. m–p Western blotting detected the protein level of VHL in H1975 ( m ) and PLC/PRF/5 cells ( o ) and decitabine effect on cell viability of VHL-depleted H1975 cells ( n ) and PLC/PRF/5 ( p ). Data are shown as the mean ± s.d., n = 3. ** P < 0.01, **** P < 0.001 between two indicated groups, Student’s t -test.
    Epigenetics Compounds Library, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/epigenetics+compound+library/Epigenetics+Compound+Library/pmc13049176-52-0-11
    Average 94 stars, based on 1 article reviews
    epigenetics compounds library - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    94
    TargetMol epigenetic inhibitors
    a Stable overexpression of VHL-HA plasmid in 786-O cells (a VHL mutated RCC cell). Western blotting detected the protein level of VHL, HA tag and its downstream target genes HIF-2α in this VHL-isogenic 786-O cell pair. Data are shown as the mean ± s.d., n = 3. b A schematic diagram of synthetic lethal drug screen using VHL-isogenic 786-O cell pair on the <t>Epigenetics</t> Compound Library. c Selectivity index (fold-difference in IC 50 values between VHL −/− and wtVHL OE cells) plot to identify top five synthetic lethal drug candidates. d–g Dose–response curve of 786-O VHL-isogenic cell pair ( d ) and VHL non-isogenic cell pair ( f ) treated with decitabine for 72 h. Data are shown as the mean ± s.d., n = 3. The representative images of cell density with the indicated concentration of decitabine for wtVHL OE and VHL −/− ( e ) and Caki-1 and 769-p ( g ) cells. h , i Azacitidine effect on cell viability in 786-O VHL-isogenic cell pair ( h ) and VHL non-isogenic cell pair ( i ). Data are shown as the mean ± s.d., n = 3. ** P < 0.01, *** P < 0.001 between two indicated groups, Student’s t -test. j , k Dose–response curve of 786-O VHL-isogenic cell pair treated with RC-3117 ( j ) and SGI-1027 ( k ). Data are shown as the mean ± s.d., n = 3. l Chemical structures of DNMT inhibitors used in this study. m–p Western blotting detected the protein level of VHL in H1975 ( m ) and PLC/PRF/5 cells ( o ) and decitabine effect on cell viability of VHL-depleted H1975 cells ( n ) and PLC/PRF/5 ( p ). Data are shown as the mean ± s.d., n = 3. ** P < 0.01, **** P < 0.001 between two indicated groups, Student’s t -test.
    Epigenetic Inhibitors, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/epigenetics+compound+library/Histone+Modification+Compound+Library/pm41713838-53-7-15
    Average 94 stars, based on 1 article reviews
    epigenetic inhibitors - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    94
    TargetMol epigenetic drug screening 108
    a Stable overexpression of VHL-HA plasmid in 786-O cells (a VHL mutated RCC cell). Western blotting detected the protein level of VHL, HA tag and its downstream target genes HIF-2α in this VHL-isogenic 786-O cell pair. Data are shown as the mean ± s.d., n = 3. b A schematic diagram of synthetic lethal drug screen using VHL-isogenic 786-O cell pair on the <t>Epigenetics</t> Compound Library. c Selectivity index (fold-difference in IC 50 values between VHL −/− and wtVHL OE cells) plot to identify top five synthetic lethal drug candidates. d–g Dose–response curve of 786-O VHL-isogenic cell pair ( d ) and VHL non-isogenic cell pair ( f ) treated with decitabine for 72 h. Data are shown as the mean ± s.d., n = 3. The representative images of cell density with the indicated concentration of decitabine for wtVHL OE and VHL −/− ( e ) and Caki-1 and 769-p ( g ) cells. h , i Azacitidine effect on cell viability in 786-O VHL-isogenic cell pair ( h ) and VHL non-isogenic cell pair ( i ). Data are shown as the mean ± s.d., n = 3. ** P < 0.01, *** P < 0.001 between two indicated groups, Student’s t -test. j , k Dose–response curve of 786-O VHL-isogenic cell pair treated with RC-3117 ( j ) and SGI-1027 ( k ). Data are shown as the mean ± s.d., n = 3. l Chemical structures of DNMT inhibitors used in this study. m–p Western blotting detected the protein level of VHL in H1975 ( m ) and PLC/PRF/5 cells ( o ) and decitabine effect on cell viability of VHL-depleted H1975 cells ( n ) and PLC/PRF/5 ( p ). Data are shown as the mean ± s.d., n = 3. ** P < 0.01, **** P < 0.001 between two indicated groups, Student’s t -test.
    Epigenetic Drug Screening 108, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/epigenetics+compound+library/Hematopoietic+Toxicity+Compound+Library/pm41713838-53-2-15
    Average 94 stars, based on 1 article reviews
    epigenetic drug screening 108 - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    96
    Selleck Chemicals epigenetics 135 compound library
    a Stable overexpression of VHL-HA plasmid in 786-O cells (a VHL mutated RCC cell). Western blotting detected the protein level of VHL, HA tag and its downstream target genes HIF-2α in this VHL-isogenic 786-O cell pair. Data are shown as the mean ± s.d., n = 3. b A schematic diagram of synthetic lethal drug screen using VHL-isogenic 786-O cell pair on the <t>Epigenetics</t> Compound Library. c Selectivity index (fold-difference in IC 50 values between VHL −/− and wtVHL OE cells) plot to identify top five synthetic lethal drug candidates. d–g Dose–response curve of 786-O VHL-isogenic cell pair ( d ) and VHL non-isogenic cell pair ( f ) treated with decitabine for 72 h. Data are shown as the mean ± s.d., n = 3. The representative images of cell density with the indicated concentration of decitabine for wtVHL OE and VHL −/− ( e ) and Caki-1 and 769-p ( g ) cells. h , i Azacitidine effect on cell viability in 786-O VHL-isogenic cell pair ( h ) and VHL non-isogenic cell pair ( i ). Data are shown as the mean ± s.d., n = 3. ** P < 0.01, *** P < 0.001 between two indicated groups, Student’s t -test. j , k Dose–response curve of 786-O VHL-isogenic cell pair treated with RC-3117 ( j ) and SGI-1027 ( k ). Data are shown as the mean ± s.d., n = 3. l Chemical structures of DNMT inhibitors used in this study. m–p Western blotting detected the protein level of VHL in H1975 ( m ) and PLC/PRF/5 cells ( o ) and decitabine effect on cell viability of VHL-depleted H1975 cells ( n ) and PLC/PRF/5 ( p ). Data are shown as the mean ± s.d., n = 3. ** P < 0.01, **** P < 0.001 between two indicated groups, Student’s t -test.
    Epigenetics 135 Compound Library, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/epigenetics+compound+library/Compound/10__1093_slash_noajnl_slash_vdag037-57-45-50
    Average 96 stars, based on 1 article reviews
    epigenetics 135 compound library - by Bioz Stars, 2026-10
    96/100 stars
      Buy from Supplier

    Image Search Results


    High-throughput drug screen and MEK inhibitor sensitivity in MRTX1719-resistant NSCLC cells. (A) Composition of the compound library used for drug screen, including SGC epigenetic compounds, FDA-approved oncology drugs, and TargetMol epigenetic inhibitors. (B) IC50 values of MRTX1719 and anisomycin in DMSO and MRTXR cells. Anisomycin was included as a nonselective control in the drug screen. (C) Dose-response curves of DMSO and MRTXR cells treated with the MEK inhibitor selumetinib. Data are presented as mean ± SD. (D) Synergy heatmaps of MRTX1719 and selumetinib in DMSO and MRTXR cells. Synergy mean scores were calculated using the Bliss model with the SynergyFinder+ tool.

    Journal: bioRxiv

    Article Title: Acquired resistance to the PRMT5 inhibitor confers collateral sensitivity to MEK inhibition in MTAP-null non-small cell lung cancer

    doi: 10.64898/2026.04.16.719008

    Figure Lengend Snippet: High-throughput drug screen and MEK inhibitor sensitivity in MRTX1719-resistant NSCLC cells. (A) Composition of the compound library used for drug screen, including SGC epigenetic compounds, FDA-approved oncology drugs, and TargetMol epigenetic inhibitors. (B) IC50 values of MRTX1719 and anisomycin in DMSO and MRTXR cells. Anisomycin was included as a nonselective control in the drug screen. (C) Dose-response curves of DMSO and MRTXR cells treated with the MEK inhibitor selumetinib. Data are presented as mean ± SD. (D) Synergy heatmaps of MRTX1719 and selumetinib in DMSO and MRTXR cells. Synergy mean scores were calculated using the Bliss model with the SynergyFinder+ tool.

    Article Snippet: The screening library comprised 619 compounds, including SGC epigenetic compounds, TargetMol epigenetic inhibitors, and FDA-approved oncology drugs ( ).

    Techniques: High Throughput Screening Assay, Drug discovery, Control

    High-throughput drug screen and MEK inhibitor sensitivity in MRTX1719-resistant NSCLC cells. (A) Composition of the compound library used for drug screen, including SGC epigenetic compounds, FDA-approved oncology drugs, and TargetMol epigenetic inhibitors. (B) IC50 values of MRTX1719 and anisomycin in DMSO and MRTXR cells. Anisomycin was included as a nonselective control in the drug screen. (C) Dose-response curves of DMSO and MRTXR cells treated with the MEK inhibitor selumetinib. Data are presented as mean ± SD. (D) Synergy heatmaps of MRTX1719 and selumetinib in DMSO and MRTXR cells. Synergy mean scores were calculated using the Bliss model with the SynergyFinder+ tool.

    Journal: bioRxiv

    Article Title: Acquired resistance to the PRMT5 inhibitor confers collateral sensitivity to MEK inhibition in MTAP-null non-small cell lung cancer

    doi: 10.64898/2026.04.16.719008

    Figure Lengend Snippet: High-throughput drug screen and MEK inhibitor sensitivity in MRTX1719-resistant NSCLC cells. (A) Composition of the compound library used for drug screen, including SGC epigenetic compounds, FDA-approved oncology drugs, and TargetMol epigenetic inhibitors. (B) IC50 values of MRTX1719 and anisomycin in DMSO and MRTXR cells. Anisomycin was included as a nonselective control in the drug screen. (C) Dose-response curves of DMSO and MRTXR cells treated with the MEK inhibitor selumetinib. Data are presented as mean ± SD. (D) Synergy heatmaps of MRTX1719 and selumetinib in DMSO and MRTXR cells. Synergy mean scores were calculated using the Bliss model with the SynergyFinder+ tool.

    Article Snippet: A high-throughput drug screen was performed using a compound library consisting of 619 compounds, including 59 SGC epigenetic compounds, 380 TargetMol epigenetic inhibitors and 180 FDA-approved oncology drugs.

    Techniques: High Throughput Screening Assay, Drug discovery, Control

    High-throughput drug screen and MEK inhibitor sensitivity in MRTX1719-resistant NSCLC cells. (A) Composition of the compound library used for drug screen, including SGC epigenetic compounds, FDA-approved oncology drugs, and TargetMol epigenetic inhibitors. (B) IC50 values of MRTX1719 and anisomycin in DMSO and MRTXR cells. Anisomycin was included as a nonselective control in the drug screen. (C) Dose-response curves of DMSO and MRTXR cells treated with the MEK inhibitor selumetinib. Data are presented as mean ± SD. (D) Synergy heatmaps of MRTX1719 and selumetinib in DMSO and MRTXR cells. Synergy mean scores were calculated using the Bliss model with the SynergyFinder+ tool.

    Journal: bioRxiv

    Article Title: Acquired resistance to the PRMT5 inhibitor confers collateral sensitivity to MEK inhibition in MTAP-null non-small cell lung cancer

    doi: 10.64898/2026.04.16.719008

    Figure Lengend Snippet: High-throughput drug screen and MEK inhibitor sensitivity in MRTX1719-resistant NSCLC cells. (A) Composition of the compound library used for drug screen, including SGC epigenetic compounds, FDA-approved oncology drugs, and TargetMol epigenetic inhibitors. (B) IC50 values of MRTX1719 and anisomycin in DMSO and MRTXR cells. Anisomycin was included as a nonselective control in the drug screen. (C) Dose-response curves of DMSO and MRTXR cells treated with the MEK inhibitor selumetinib. Data are presented as mean ± SD. (D) Synergy heatmaps of MRTX1719 and selumetinib in DMSO and MRTXR cells. Synergy mean scores were calculated using the Bliss model with the SynergyFinder+ tool.

    Article Snippet: A high-throughput drug screen was performed using a compound library consisting of 619 compounds, including 59 SGC epigenetic compounds, 380 TargetMol epigenetic inhibitors and 180 FDA-approved oncology drugs.

    Techniques: High Throughput Screening Assay, Drug discovery, Control

    a Stable overexpression of VHL-HA plasmid in 786-O cells (a VHL mutated RCC cell). Western blotting detected the protein level of VHL, HA tag and its downstream target genes HIF-2α in this VHL-isogenic 786-O cell pair. Data are shown as the mean ± s.d., n = 3. b A schematic diagram of synthetic lethal drug screen using VHL-isogenic 786-O cell pair on the Epigenetics Compound Library. c Selectivity index (fold-difference in IC 50 values between VHL −/− and wtVHL OE cells) plot to identify top five synthetic lethal drug candidates. d–g Dose–response curve of 786-O VHL-isogenic cell pair ( d ) and VHL non-isogenic cell pair ( f ) treated with decitabine for 72 h. Data are shown as the mean ± s.d., n = 3. The representative images of cell density with the indicated concentration of decitabine for wtVHL OE and VHL −/− ( e ) and Caki-1 and 769-p ( g ) cells. h , i Azacitidine effect on cell viability in 786-O VHL-isogenic cell pair ( h ) and VHL non-isogenic cell pair ( i ). Data are shown as the mean ± s.d., n = 3. ** P < 0.01, *** P < 0.001 between two indicated groups, Student’s t -test. j , k Dose–response curve of 786-O VHL-isogenic cell pair treated with RC-3117 ( j ) and SGI-1027 ( k ). Data are shown as the mean ± s.d., n = 3. l Chemical structures of DNMT inhibitors used in this study. m–p Western blotting detected the protein level of VHL in H1975 ( m ) and PLC/PRF/5 cells ( o ) and decitabine effect on cell viability of VHL-depleted H1975 cells ( n ) and PLC/PRF/5 ( p ). Data are shown as the mean ± s.d., n = 3. ** P < 0.01, **** P < 0.001 between two indicated groups, Student’s t -test.

    Journal: Experimental & Molecular Medicine

    Article Title: DNA methyltransferase inhibition is a therapeutic vulnerability in VHL-deficient renal cell carcinoma cells

    doi: 10.1038/s12276-026-01663-w

    Figure Lengend Snippet: a Stable overexpression of VHL-HA plasmid in 786-O cells (a VHL mutated RCC cell). Western blotting detected the protein level of VHL, HA tag and its downstream target genes HIF-2α in this VHL-isogenic 786-O cell pair. Data are shown as the mean ± s.d., n = 3. b A schematic diagram of synthetic lethal drug screen using VHL-isogenic 786-O cell pair on the Epigenetics Compound Library. c Selectivity index (fold-difference in IC 50 values between VHL −/− and wtVHL OE cells) plot to identify top five synthetic lethal drug candidates. d–g Dose–response curve of 786-O VHL-isogenic cell pair ( d ) and VHL non-isogenic cell pair ( f ) treated with decitabine for 72 h. Data are shown as the mean ± s.d., n = 3. The representative images of cell density with the indicated concentration of decitabine for wtVHL OE and VHL −/− ( e ) and Caki-1 and 769-p ( g ) cells. h , i Azacitidine effect on cell viability in 786-O VHL-isogenic cell pair ( h ) and VHL non-isogenic cell pair ( i ). Data are shown as the mean ± s.d., n = 3. ** P < 0.01, *** P < 0.001 between two indicated groups, Student’s t -test. j , k Dose–response curve of 786-O VHL-isogenic cell pair treated with RC-3117 ( j ) and SGI-1027 ( k ). Data are shown as the mean ± s.d., n = 3. l Chemical structures of DNMT inhibitors used in this study. m–p Western blotting detected the protein level of VHL in H1975 ( m ) and PLC/PRF/5 cells ( o ) and decitabine effect on cell viability of VHL-depleted H1975 cells ( n ) and PLC/PRF/5 ( p ). Data are shown as the mean ± s.d., n = 3. ** P < 0.01, **** P < 0.001 between two indicated groups, Student’s t -test.

    Article Snippet: Epigenetics compounds library contains 138 small molecules which was purchased from Selleck Chemicals.

    Techniques: Over Expression, Plasmid Preparation, Western Blot, Drug discovery, Concentration Assay